# A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Source: https://onco.cc/trials/nct06994676/  
OnCo record `nct06994676` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CBX-250 run by Crossbow Therapeutics, Inc., now recruiting.

## Summary

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias is a phase 1 interventional study registered as NCT06994676 by Crossbow Therapeutics, Inc., with 72 participants planned, started 2025-07-16. Conditions recorded: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia and Chronic Myeloid Leukemia. Interventions recorded: CBX-250.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06994676
- Phase: 1
- Setting: CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Sponsor: Crossbow Therapeutics, Inc.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT06994676: https://clinicaltrials.gov/study/NCT06994676

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [CBX-250](https://onco.cc/drugs/cbx-250/)
- companies: [Crossbow Therapeutics](https://onco.cc/companies/crossbow-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06994676.json